Speaker Companion: Polypharmacy in TRD

45 min | Psychopharmacology Focus

Slide 03 Augmentation Efficacy10 min

Speaker Notes

  • Emphasize VAST-D trial for aripiprazole
  • Why switching is less effective (treatment failure ≠ wrong drug)
  • Combination therapy as preferred strategy
💡 Teaching Point: "Treatment-resistant" often means "combination-naive"
Q: "What if patient failed SSRI + mirtazapine?" Hard
Consider atypical antipsychotic augmentation. Quetiapine or aripiprazole both evidence-based. Monitor metabolic effects.